Novartis AG
NEW THERAPEUTIC USES

Abstract:

The present invention provides nazartinib, or a pharmaceutically acceptable salt thereof, preferably the mesylate salt thereof, for use in treating or preventing Central Nervous System (CNS) metastasis, brain metastasis, and/or leptomeningeal metastasis, particularly when the CNS or brain metastasis, or leptomeningeal metastasis is present in a patient with locally advanced or metastatic NSCLC.